KIT and neoplasm: Although recent results in clinical trials using the tyrosine kinase receptor inhibitor imatinib mesylate, which targets PDGFR and c-Kit, have not been encouraging (Mathy, 2005; Porta, 2007), it is to be hoped that the common effort of medical and research disciplines will in the future allow us to achieve more success in treating this highly lethal tumor.